BFC
FLNA

Bedel Financial Consulting’s Filana Therapeutics FLNA Stock Holding History

Bedel Financial Consulting’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-28
Closed -$1K – 747
2022
Q1 		$1K Hold
28
– – ﹤0.01% 938
2021
Q4 		$1K Buy
+28
New +$1.47K ﹤0.01% 968

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bedel Financial Consulting's FLNA Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Filana Therapeutics (FLNA) in Q2 2022, closing a stake of 28 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in FLNA in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 149 funds tracked by Wall St. Rank hold FLNA as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Filana Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 28 Filana Therapeutics shares in Q2 2022, an estimated $1K.
  • Bedel Financial Consulting first reported a position in Filana Therapeutics in Q4 2021 and held it in 2 quarters.
  • Bedel Financial Consulting's Filana Therapeutics position peaked at $1K in Q1 2022.
  • 149 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.